The Use of Statins for Myocardial Death Prevention

NCT00772564

Last updated date
Study Location
Rambam Health Care Campus
Haifa, , 31096, Israel
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Myocardial Infarction
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
30-90 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

1. Patients suffering from acute ST elevation resulting from myocardial infarction, Killip Classification 1 and 2 will be included at-random to either group. Included subjects should be able to give their informed consent to participate in this study.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


1. The impossibility to give the required informed consent.


2. Known allergy to Atorvastatin.


3. Base line serum creatinine of 1.4 mg/dL.


4. Killip Classification 3 and 4.


5. Persisting vomiting.


6. History of previous liver disease.


7. History of previous muscle disease or rabdomyolisis.


8. Treated already with high dose atorvastatin


9. Non Compliance.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Myocardial InfarctionAPRICOT-3: Antithrombotics in the Prevention of Reocclusion In COronary Thrombolysis -3
NCT00138034
  1. Nijmegen, Gelderland
ALL GENDERS
0+
years
MULTIPLE SITES
Myocardial InfarctionThe Use of Statins for Myocardial Death Prevention
NCT00772564
  1. Haifa,
ALL GENDERS
30 Years+
years
MULTIPLE SITES
Myocardial InfarctionImpact Of Eplerenone On Cardiovascular Outcomes In Patients Post Myocardial Infarction
NCT01176968
  1. Edmonton, Alberta
  2. Edmonton, Alberta
  3. Vancouver, British Columbia
  4. Vancouver, British Columbia
  5. Vancouver, British Columbia
  6. St. John's, Newfoundland and Labrador
  7. Toronto, Ontario
  8. Toronto, Ontario
  9. Chicoutimi, Quebec
  10. Chicoutimi, Quebec
  11. Sherbrooke, Quebec
  12. Brno,
  13. Hradec Kralove,
  14. Hradec Kralove,
  15. Olomouc,
  16. Olomouc,
  17. Praha 4,
  18. Praha 5,
  19. Toulouse, Cedex 4
  20. Dijon, Cedex
  21. Paris, Cedex
  22. Cannes,
  23. Creteil,
  24. Creteil,
  25. Evecquemont,
  26. Libourne,
  27. Pessac Cedex,
  28. Bad Krozingen,
  29. Berlin,
  30. Bonn,
  31. Bremen,
  32. Dortmund,
  33. Dortmund,
  34. Dresden,
  35. Goettingen,
  36. Hamburg,
  37. Hannover,
  38. Limburg,
  39. Mainz,
  40. Munich,
  41. Athens,
  42. Athens,
  43. Rio Patra,
  44. Budapest,
  45. Gyor,
  46. Nyiregyhaza,
  47. Zalaegerszeg,
  48. Amsterdam,
  49. Nieuwegein,
  50. Bydgoszcz,
  51. Olsztyn,
  52. Oswiecim,
  53. Wroclaw,
  54. Banska Bystrica,
  55. Bratislava,
  56. Martin,
  57. Nitra,
  58. Rimavska Sobota,
  59. Jerez de la Frontera, Cadiz
  60. Barcelona,
  61. Barcelona,
  62. Madrid,
  63. Madrid,
  64. Palma de Mallorca,
  65. Valencia,
  66. Blackpool, Lancashire
  67. Edinburgh, Lothian
  68. Swansea, Wales
  69. Birmingham,
  70. Cottingham Hull,
  71. Coventry,
  72. Dundee,
  73. Edinburgh,
  74. Leicester,
  75. Swansea,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE The Use of Statins for Myocardial Death Prevention
Official Title  ICMJE The Use of Statins for Myocardial Death Prevention: From Cell to Bedside
Brief Summary The administration of high dose HMG-CoA reductase inhibitors (Statins) to patients with acute ST-elevation MI (hypoxia/ischemia) who are treated with primary PCI (reoxygenation/ reperfusion) will protect their cardiomyocytes from death and thus preserve LV ejection fraction.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 4
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Condition  ICMJE Myocardial Infarction
Intervention  ICMJE Drug: Atorvastatin
Oral Atorvastatin
Study Arms  ICMJE
  • Experimental: Atorvastatin 80 mg
    Intervention: Drug: Atorvastatin
  • Experimental: Atorvastatin 10 mg
    Intervention: Drug: Atorvastatin
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: May 25, 2012)
25
Original Estimated Enrollment  ICMJE
 (submitted: October 14, 2008)
60
Actual Study Completion Date  ICMJE August 2010
Actual Primary Completion Date June 2010   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

1. Patients suffering from acute ST elevation resulting from myocardial infarction, Killip Classification 1 and 2 will be included at-random to either group. Included subjects should be able to give their informed consent to participate in this study.

Exclusion Criteria:

  1. The impossibility to give the required informed consent.
  2. Known allergy to Atorvastatin.
  3. Base line serum creatinine of 1.4 mg/dL.
  4. Killip Classification 3 and 4.
  5. Persisting vomiting.
  6. History of previous liver disease.
  7. History of previous muscle disease or rabdomyolisis.
  8. Treated already with high dose atorvastatin
  9. Non Compliance.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 30 Years to 90 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Israel
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00772564
Other Study ID Numbers  ICMJE Ator2685Hdm2[2]
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party N_Krivoy, Rambam Health Care Campus
Study Sponsor  ICMJE Rambam Health Care Campus
Collaborators  ICMJE Pfizer
Investigators  ICMJE
Principal Investigator:Sammer Diab, MD, PhDRambam Health Care Campus
PRS Account Rambam Health Care Campus
Verification Date May 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP